Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Cipla's US sales are expected to be adversely impacted by price erosion and supply disruptions for tumor drug Lanreotide, ...

Stay informed with the Cipla Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...

The market may remain in positive terrain amid elevated volatility. Below are some trading ideas for the near term.

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

The Nifty breached the 23,000 mark intra-day for the first time since June 2024, closing at 23,025, down 320 points. The ...

Read here for an analysis of PayPal's potential for growth in 2025, supported by strong cash flow and margins, driving a buy ...

Cipla share price has risen by 10% over the past 12 months and 64% over the last three years. The company's current market ...

Cipla on Monday (January 20) announced that the United States Food and Drug Administration conducted an inspection of its ...

Citi raised the firm’s price target on PayPal (PYPL) to $97 from $94 and keeps a Buy rating on the shares as part of a 2025 preview for the ...

In a major win for Cipla Ltd., the National Pharmaceutical Pricing Authority (NPPA) has issued a revised calculation sheet ...

The Pharma sector outperformed in 2024, gaining 29%, driven by resilience to macro challenges, US FDA resolutions, and ...